Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Combined Hepatitis A/B Vaccine with Novartis MenACWY Conjugate Vaccine in Healthy Adults
2011-001333-17Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2011
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hepatitis A + hepatitis B vaccine and menacwy conjugate vaccine in hepatitis A (HAV), hepatitis B (HBV) and meningococcal meningitis, sponsored by Novartis. Primary endpoint: Primary immunogenicity endpoints. Started Jun 2011; status: completed.
02
Drugs
hepatitis A + hepatitis B vaccinemenacwy conjugate vaccine
03
Conditions
hepatitis A (HAV)hepatitis B (HBV)meningococcal meningitis
Beyond the preview
Go deeper on 2011-001333-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001333-17.